{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:01:46Z","timestamp":1793289706741,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1A2C2007430"],"award-info":[{"award-number":["2021R1A2C2007430"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017051","name":"Seoul National University College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017239","name":"BeiGene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017239","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jhep.2025.10.032","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T16:18:48Z","timestamp":1764001128000},"page":"766-775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1456-2392","authenticated-orcid":false,"given":"Jeesun","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choong-kun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5177-8937","authenticated-orcid":false,"given":"Beodeul","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Jun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6979-5812","authenticated-orcid":false,"given":"Hong Jae","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1204-0574","authenticated-orcid":false,"given":"Myung Ah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-9901","authenticated-orcid":false,"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2025.10.032_bib1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.10.032_bib2","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1200\/JCO.21.02576","article-title":"Precision medicine in biliary tract cancer","volume":"40","author":"Scott","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.032_bib3","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhep.2025.10.032_bib4","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jhep.2025.10.032_bib5","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2025.05.003","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"83","author":"Oh","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.032_bib6","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.10.032_bib7","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4093","article-title":"Three-year follow-up data from KEYNOTE-966: pembrolizumab (pembro) plus gemcitabine and cisplatin (gem\/cis) compared with gem\/cis alone for patients (pts) with advanced biliary tract cancer (BTC)","volume":"42","author":"Finn","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.032_bib8","series-title":"FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion","year":"2020"},{"key":"10.1016\/j.jhep.2025.10.032_bib9","series-title":"FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma","year":"2021"},{"key":"10.1016\/j.jhep.2025.10.032_bib10","unstructured":"FDA grants accelerated approval to zanidatamab-hrii for previously treated unresectable or metastatic HER2-positive biliary tract cancer 2024 [Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zanidatamab-hrii-previously-treated-unresectable-or-metastatic-her2."},{"key":"10.1016\/j.jhep.2025.10.032_bib11","unstructured":"FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors 2024 [Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2."},{"key":"10.1016\/j.jhep.2025.10.032_bib12","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2025.10.032_bib13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2025.10.032_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104003","article-title":"EGCEa. ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer","volume":"10","author":"Vogel","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.jhep.2025.10.032_bib15","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","article-title":"Development of immunotherapy combination strategies in cancer","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.jhep.2025.10.032_bib16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41571-024-00886-y","article-title":"Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials","volume":"21","author":"Kuo","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.032_bib17","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124184","article-title":"Sitravatinib potentiates immune checkpoint blockade in refractory cancer models","volume":"3","author":"Du","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jhep.2025.10.032_bib18","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jtho.2023.02.016","article-title":"MRTX-500 phase 2 trial: sitravatinib with nivolumab in patients with nonsquamous NSCLC progressing on or after checkpoint inhibitor therapy or chemotherapy","volume":"18","author":"He","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jhep.2025.10.032_bib19","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1038\/s41467-023-38342-7","article-title":"Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma","volume":"14","author":"Karam","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2025.10.032_bib20","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/annonc\/mdu162","article-title":"Second-line chemotherapy in advanced biliary cancer: a systematic review","volume":"25","author":"Lamarca","year":"2014","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.jhep.2025.10.032_bib21","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jhep.2025.03.013","article-title":"Liposomal irinotecan for previously treated patients with biliary tract cancer: a pooled analysis of NIFTY and NALIRICC trials","volume":"83","author":"Yoo","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.032_bib22","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2025.10.032_bib23","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhep.2025.10.032_bib24","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/cam4.4593","article-title":"Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer","volume":"11","author":"Doki","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.jhep.2025.10.032_bib25","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jamaoncol.2020.2814","article-title":"Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial","volume":"6","author":"Klein","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2025.10.032_bib26","article-title":"Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study","volume":"39","author":"Villanueva","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.032_bib27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejca.2021.11.012","article-title":"Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial","volume":"162","author":"Cousin","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2025.10.032_bib28","article-title":"The efficacy and safety of apatinib plus camrelizumab in patients with previously treated advanced biliary tract cancer: a prospective clinical study","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhep.2025.10.032_bib29","doi-asserted-by":"crossref","DOI":"10.1172\/JCI180893","article-title":"Tumor-initiating cells escape tumor immunity via CCL8 from tumor-associated macrophages in mice","volume":"135","author":"Chen","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2025.10.032_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100049","article-title":"Homologous recombination repair deficiency: an overview for pathologists","volume":"36","author":"Doig","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jhep.2025.10.032_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.871756","article-title":"Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma","volume":"13","author":"You","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2025.10.032_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15235608","article-title":"Homologous recombination repair gene alterations are associated with tumor mutational burden and survival of immunotherapy","volume":"15","author":"Ito","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2025.10.032_bib33","series-title":"Homologous recombination deficiency status predicts response to immunotherapy-based treatment in non-small cell lung cancer patients","author":"Gao","year":"2024"},{"key":"10.1016\/j.jhep.2025.10.032_bib34","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cjp2.271","article-title":"Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types","volume":"8","author":"Budczies","year":"2022","journal-title":"J Pathol Clin Res"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825026261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825026261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:57:25Z","timestamp":1777528645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827825026261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0168827825026261"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2025.10.032","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.10.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}